Silexion Therapeutics Corp
SLXN
$3.78
$0.051.34%
NASDAQ
12/31/2024 | |||||
---|---|---|---|---|---|
Revenue | -- | ||||
Total Other Revenue | -- | ||||
Total Revenue | -- | ||||
Cost of Revenue | -- | ||||
Gross Profit | -- | ||||
SG&A Expenses | 359.04% | ||||
Depreciation & Amortization | -- | ||||
Other Operating Expenses | -- | ||||
Total Operating Expenses | 389.22% | ||||
Operating Income | -389.22% | ||||
Income Before Tax | -363.72% | ||||
Income Tax Expenses | 1,050.00% | ||||
Earnings from Continuing Operations | -363.84% | ||||
Earnings from Discontinued Operations | -- | ||||
Extraordinary Item & Accounting Change | -- | ||||
Minority Interest in Earnings | 1,788.89% | ||||
Net Income | -362.75% | ||||
EBIT | -389.22% | ||||
EBITDA | -388.36% | ||||
EPS Basic | -204.96% | ||||
Normalized Basic EPS | -204.65% | ||||
EPS Diluted | -204.96% | ||||
Normalized Diluted EPS | -204.65% | ||||
Average Basic Shares Outstanding | 150.34% | ||||
Average Diluted Shares Outstanding | 150.34% | ||||
Dividend Per Share | -- | ||||
Payout Ratio | -- |